NCT00664248已完成3 期
A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
Dow Pharmaceutical Sciences35 个研究点 分布在 3 个国家目标入组 1,414 人开始时间: 2006年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,414
- 试验地点
- 35
- 主要终点
- Change from baseline in number of lesions
研究概览
简要总结
The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of inflammatory and non-inflammatory lesions
排除标准
- •Dermatological conditions of the face other than acne that could interfere with clinical evaluations
- •Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
研究组 & 干预措施
2
Active Comparator
干预措施: Clindamycin (Drug)
1
Experimental
干预措施: IDP-110 (Drug)
3
Active Comparator
干预措施: Benzoyl peroxide (Drug)
4
Placebo Comparator
干预措施: Vehicle (Drug)
结局指标
主要结局
Change from baseline in number of lesions
时间窗: 12 weeks
次要结局
- Change from baseline in global severity(12 weeks)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
3 期
A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne VulgarisAcne VulgarisNCT00663286Dow Pharmaceutical Sciences1,399
进行中（未招募）
1 期
Therapy-treatment (PDT) on Acne, a study to optimize the number of treatments, the right light-dose and the right pre-treatment in order to obtain a longterm remission-timeAcneEUCTR2014-005235-13-SESahlgrenska University hospital of gothenburg Department of dermatology46
撤回
1 期
An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne VulgarisAcne VulgarisNCT01785836Allergan
进行中（未招募）
3 期
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Alzheimer DiseaseNCT04437511Eli Lilly and Company1,736
终止
4 期
Clinical Study to Evaluate the Safety and Efficacy of the Vela100Cellulite ReductionCircumference ReductionNCT01026441Syneron Medical60